BACKGROUND & AIMS: Bioavailability of insulin-like growth factor (IGF-I) is reduced in liver cirrhosis. The aim of this study was to analyze the effect of IGF-I on liver histopathology and function in experimental cirrhosis. METHODS: Rats received CCl4 inhalations for 11 or 30 weeks (protocols 1 and 2, respectively) and were treated with 2 microg x 100 g body wt(-1) x day(-1) IGF-I (group CI + IGF) or saline (group CI) on weeks 13 and 14 (protocol 1) or on weeks 28-30 (protocol 2). Normal rats were studied in parallel. RESULTS: Serum albumin and total protein levels were reduced in CI but not in CI + IGF rats compared with normal rats. Clotting factors II, VII, and X were significantly greater in CI + IGF than in CI rats. Liver lipid peroxidation products were significantly increased in CI but not in CI + IGF rats, and liver fibrosis was less pronounced in CI + IGF than in CI animals. The activities of antioxidant enzymes and mitochondrial transmembrane potential were reduced compared with normal animals in CI but not in CI + IGF rats. CONCLUSIONS: IGF-I improves liver function and reduces oxidative liver damage and fibrosis in rats with compensated or advanced liver cirrhosis. Improved mitochondrial function could play a role in the hepatoprotective effect of this hormone.
BACKGROUND & AIMS: Bioavailability of insulin-like growth factor (IGF-I) is reduced in liver cirrhosis. The aim of this study was to analyze the effect of IGF-I on liver histopathology and function in experimental cirrhosis. METHODS:Rats received CCl4 inhalations for 11 or 30 weeks (protocols 1 and 2, respectively) and were treated with 2 microg x 100 g body wt(-1) x day(-1) IGF-I (group CI + IGF) or saline (group CI) on weeks 13 and 14 (protocol 1) or on weeks 28-30 (protocol 2). Normal rats were studied in parallel. RESULTS: Serum albumin and total protein levels were reduced in CI but not in CI + IGF rats compared with normal rats. Clotting factors II, VII, and X were significantly greater in CI + IGF than in CI rats. Liver lipid peroxidation products were significantly increased in CI but not in CI + IGF rats, and liver fibrosis was less pronounced in CI + IGF than in CI animals. The activities of antioxidant enzymes and mitochondrial transmembrane potential were reduced compared with normal animals in CI but not in CI + IGF rats. CONCLUSIONS:IGF-I improves liver function and reduces oxidative liver damage and fibrosis in rats with compensated or advanced liver cirrhosis. Improved mitochondrial function could play a role in the hepatoprotective effect of this hormone.
Authors: M García-Fernández; I Castilla-Cortázar; M Díaz-Sánchez; F Díez Caballero; A Castilla; A Díaz Casares; I Varela-Nieto; S González-Barón Journal: J Physiol Biochem Date: 2003-06 Impact factor: 4.158
Authors: V Lorenzo-Zúñiga; C M Rodríguez-Ortigosa; R Bartolí; M-L Martínez-Chantar; L Martínez-Peralta; A Pardo; I Ojanguren; J Quiroga; R Planas; J Prieto Journal: Gut Date: 2006-01-24 Impact factor: 23.059
Authors: S Sanz; J B Pucilowska; S Liu; C M Rodríguez-Ortigosa; P K Lund; D A Brenner; C R Fuller; J G Simmons; A Pardo; M-L Martínez-Chantar; J A Fagin; J Prieto Journal: Gut Date: 2005-01 Impact factor: 23.059
Authors: Carmen Castillo; Veronica Salazar; Carmen Ariznavarreta; Elena Vara; Jesus A F Tresguerres Journal: Endocrine Date: 2005-02 Impact factor: 3.633
Authors: Chiranjeev Dash; Teletia R Taylor; Kepher H Makambi; Jennifer Hicks; James M Hagberg; Lucile L Adams-Campbell Journal: Cancer Date: 2018-07-05 Impact factor: 6.860
Authors: I Castilla-Cortazar; L Guerra; J E Puche; U Muñoz; R Barhoum; E Escudero; J L Lavandera Journal: J Physiol Biochem Date: 2013-09-18 Impact factor: 4.158